Key result
Vasodilator therapy, notably angiotensin-converting enzyme inhibitors, improves survival, hemodynamics, and quality of life in patients with congestive heart failure and depressed systolic function.
Why the study?
Does vasodilator therapy improve survival and symptoms in patients with congestive heart failure?
Population
Patients with congestive heart failure and depressed left ventricular systolic function
Design
Review
Authors
Loading...
Supports ACEI use in systolic HF; leaves open optimal combinations with modern therapies.
Does vasodilator therapy improve survival and symptoms in patients with congestive heart failure?
Vasodilator therapy, especially ACE inhibitors, is strongly recommended for widespread use in patients with congestive heart failure and left ventricular systolic dysfunction due to demonstrated survival and functional benefits.
David L. Groden (1993) conducted a review in Congestive heart failure. Vasodilator therapy (angiotensin-converting enzyme inhibitors) was evaluated. Vasodilator therapy, notably angiotensin-converting enzyme inhibitors, improves survival, hemodynamics, and quality of life in patients with congestive heart failure and depressed systolic function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: